| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CELL.2018.04.012 |
| P698 | PubMed publication ID | 29754815 |
| P50 | author | Evert Bosdriesz | Q52609122 |
| Rodrigo Leite de Oliveira | Q55948940 | ||
| Jan H M Schellens | Q89824209 | ||
| Jos Beijnen | Q23771643 | ||
| P2093 | author name string | Rene Bernards | |
| Liqin Wang | |||
| Bastiaan Nuijen | |||
| Ji-Ying Song | |||
| Diede Brunen | |||
| Sanne Huijberts | |||
| Hugo Horlings | |||
| John Zevenhoven | |||
| Astrid Bosma | |||
| Nora Pencheva | |||
| G Tjitske Los-de Vries | |||
| P2860 | cites work | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1413-1425.e14 | |
| P577 | publication date | 2018-05-10 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential | |
| P478 | volume | 173 |
| Q61807258 | A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma |
| Q92528077 | AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma |
| Q64998591 | Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. |
| Q58712892 | Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells |
| Q92602356 | Cellular internalization of bystander nanomaterial induced by TAT-nanoparticles and regulated by extracellular cysteine |
| Q92765629 | Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma |
| Q91866768 | Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy |
| Q97088693 | Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens |
| Q92133167 | Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies |
| Q90460706 | Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency |
| Q96128431 | Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer |
| Q92130484 | Exploiting evolutionary steering to induce collateral drug sensitivity in cancer |
| Q59795693 | Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities |
| Q92544513 | Fibroblast Growth Factor Receptor Signaling in Skin Cancers |
| Q92946120 | HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma |
| Q60920855 | HGF/c-MET Signaling in Melanocytes and Melanoma |
| Q97074415 | Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma |
| Q98771751 | Histone Deacetylases Inhibit the Snail2-Mediated EMT During Metastasis of Hepatocellular Carcinoma Cells |
| Q57299883 | Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule |
| Q89001587 | Lethally high ROS levels thwart resistance |
| Q91784789 | Limited Evolutionary Conservation of the Phenotypic Effects of Antibiotic Resistance Mutations |
| Q91725276 | Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway |
| Q90043581 | Melanoma Metabolism: Cell Survival and Resistance to Therapy |
| Q96304654 | Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment |
| Q92627552 | Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance |
| Q58576103 | Next-Generation Modeling of Human Cancers |
| Q92663341 | Oxidative Stress and Cancer: Chemopreventive and Therapeutic Role of Triphala |
| Q92235860 | PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma |
| Q64250962 | PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling |
| Q91863904 | Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia |
| Q89830565 | Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy |
| Q57010854 | SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling |
| Q90080013 | Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside |
| Q89719900 | Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth |
| Q57172217 | Taking advantage of drug resistance, a new approach in the war on cancer |
| Q92663940 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy |
| Q89658448 | Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity |
| Q89638553 | The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies" |
| Q90641451 | The great escape: tumour cell plasticity in resistance to targeted therapy |
| Q64068503 | Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells |
| Q99571031 | Treatment of Advanced Melanoma: Past, Present and Future |
| Q90040642 | Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness |
| Q59795605 | Understanding tumor ecosystems by single-cell sequencing: promises and limitations |
| Q90591550 | Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer |
| Q90399200 | Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer |
| Q58130375 | With great power comes great vulnerability |
| Q99547004 | xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling |
Search more.